NCT02181465

Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.

Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Cancer Advances Inc. · Industry
• Sex: All
• Age: 18 Years – 81 Years
• Healthy volunteers: Not accepted

Summary

Pancreatic, gastric, and colorectal cancers have all been shown to overexpress the gastrin gene and to be sensitive to the trophic effects of the gastrin in animal models. The hypothesis of this study is that G17DT will elicit specific and high-affinity antibodies that will bind gastrin-17, thus preventing the trophic activity of cancer cells.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	G17DT

Timeline

• Start date: 1993-10-01
• Primary completion: 1994-05-01
• Completion: 1994-05-01
• First posted: 2014-07-04
• Last updated: 2014-07-04

Locations

1 site across 1 country: United Kingdom